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Abstract
Purpose: Triple-negative breast cancer (TNBC) has some distinctive features. The aim of the study was to compare 
clinical and breast magnetic resonance imaging (MRI) findings of TNBC with non-triple-negative breast cancer 
(nTNBC) in molecular subtypes such as ADC (apparent diffusion coefficient) values, T2-weighted (T2W) image 
intensity, shape, margin, lymph node involvement, grade, multifocality, multicentricity, bilaterality, and enhancement 
pattern differences between tumour subtypes.
Material and methods: A total of 141 patients who underwent breast biopsy at our institution between January 2010 
and June 2018 were included in this study. Patients were divided into molecular subtypes according to hormone 
receptor status, and Ki-67 index. Tumour grade, enhancement patterns, age, lymph node involvement, ADC values, 
breast imaging reporting and data system (BI-RADS) category, bilaterality, multifocality, multicentricity, margin, 
shape, and T2W image intensity were evaluated for these subtypes.
Results: ADC values were higher in triple-negative tumours than in luminal A and luminal B tumours (p = 0.010 and 
p = 0.002, respectively). Circumscribed margin, type 2 enhancement curve, and rim enhancement were significantly 
higher in triple-negative tumours (p < 0.001). No significant difference was found between the groups in terms of 
other MRI findings including bilaterality, multifocality, multicentricity, shape, and T2W image intensity (p > 0.05).
Conclusions: ADC values, circumscribed margin, and rim enhancement can provide important information about the 
tumour’s biological behaviour and the course of the disease.
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Introduction
Breast cancer is the most commonly seen type of cancer 
in women and a highly heterogeneous cancer with various 
morphological features, clinical courses, and treatment re-
sponses [1]. This diversity leads to the need for a standard-
ized management in the diagnosis and treatment of the 
disease [2,3]. Immunohistochemical markers, besides the 
classical parameters such as tumour size, grade, and lymph 
node involvement, play a considerable role in subtyping 
the disease, determining prognosis, and selecting the treat-
ment protocol [3-5]. According to the immunohistoche-
mical markers, breast cancer is divided into several sub-
types [6]. Triple-negative breast cancer (TNBC) accounts 
for about 15% of all breast cancer cases and is associated 
with a poor prognosis and a high ratio of distant recur-
rence [7-9]. Diagnosis of TNBC and distinction from other 
subgroups is essential for the treatment to be chosen. How-
ever up to 20% of immunohistochemical determinations 
of estrogen receptors (ER) and progesterone receptors 
(PR) testing may be inaccurate (false negative or positive). 
The reason for this difference can be due to variations in 
pre-analytic variables, positive threshold values, and evalu-
ation criteria [10]. The presence of the features of TNBC 
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in magnetic resonance imaging (MRI) distinguishing it 
from non-triple-negative breast cancer (nTNBC) may be 
cautionary in repetition of pathological specimen assess-
ment if required. This can lead to significant differences in 
patient management.
Routinely, mammography and breast ultrasound are 
used in the evaluation of breast cancer. Breast MRI is used 
to exclude breast cancer or diseases requiring immediate 
treatment in symptomatic patients, preoperative staging, 
and treatment selection in patients with known malig-
nancy (surgical or medical treatment, etc.). Breast MRI 
has the highest sensitivity (83-99%) in detecting breast 
cancer among imaging modalities [11]. As well as for di-
agnosis of breast cancer, MRI findings may differentiate 
breast cancer subtypes.
In this study, we aimed to retrospectively evaluate the 
differences between TNBC and nTNBC in terms of MRI 
findings and clinical features. Lesions were classified ac-
cording to immunohistochemical status. In addition, we 
aimed to evaluate parameters such as T2W image inten-
sity, margin, size, lymph node involvement, multifocality, 
multicentricity, contrast enhancement patterns, and their 
relevance within molecular subtypes.
Material and methods
Patients
Approval for the study was granted by Hacettepe Univer-
sity Faculty of Medicine’s Ethics Commission. Informed 
consent was not required because of the retrospective na-
ture of the study. 141 of 2546 women who had a biopsy- 
proven, > 5 mm mass forming invasive breast cancer 
at our institution between January 2010 and June 2018 
were included in this study. The age of the participants 
was over 18 years. Lesions which were benign, compatible 
with metastasis or malignant phyllodes tumour, less than 
5 mm in size or non-mass forming lesions, patients under 
18 years of age, patients who underwent chemotherapy 
and/or surgery before breast MRI, and patients without 
diffusion-weighted imaging (DWI) and apparent diffusion 
coefficient (ADC) maps were excluded.
Imaging
The MRI scans were acquired with the patient in prone 
position using a 1.5-Tesla MRI scanner (Signa HD, GE 
Medical Systems, USA) with a 4-channel phased array 
breast coil. The imaging protocol included the following 
sequences: axial T2W fat saturated (TR/TE 5100/90 ms, 
slice thickness [ST] = 2 mm, flip angle [FA] 90°, matrix 
256 × 256), axial echo-planar DWI (TR/TE 2500/72, 
ST = 3 mm, FA = 90°, matrix 256 × 256, diffusion gradient 
with b values of 0 and 1000 s/mm2), and axial T1-weight-
ed fast spin echo pre-contrast MR images (TR/TE 4.3/ 
2.1 ms, ST = 2 mm, FA = 90°, matrix 512 × 512). Dy-
namic breast examination was performed after the injec-
tion of intravenous contrast material (Dotarem, Guerbet, 
Roissy, France) through the antecubital vein at a dose of 
0.1 mmol/kg using a power injector (Medrad, Bayer 
HealthCare, Netherlands). After pre-contrast T1-weighted 
images, the following 5 axial T1-weighted post-contrast dy-
namic sequences (TR/TE 4.5/2.1 ms, ST = 2 mm, FA = 10°, 
matrix 512 × 512) were obtained at intervals of 90 s. 
Patients were evaluated retrospectively by consensus of 
2 radiologists. ADC values of the patients were measured 
by free hand region of interest (ROI) (Figures 1 and 2). 
Areas of haemorrhage and necrosis were not included in 
the ROI. In cases of bilateral and multifocal lesions, biopsy 
performed lesion was selected to measure the ADC value. 
If the biopsy was taken from multiple lesions, the mean 
of these lesions was calculated. Age, pathologic diagnosis 
of lesions, tumour grade, lymph node involvement, mor-
phological characteristics (margin, shape, T2 intensity), 
contrast enhancement kinetics (type 1, 2, 3), BI-RADS 
score, rim enhancement, multifocality, multicentricity, 
and bilaterality were recorded and evaluated.
Pathological examination
The pathological examination reports were reviewed to 
determine histopathological type, tumour grade, and im-
munohistochemical findings including ER, PR, and HER 
2 status. Tumours that were ER positive, HER 2 negative, 
and with Ki 67 < 14% were defined as luminal A; ER posi-
tive, HER 2 positive, and Ki 67 > 14% were defined as 
luminal B; ER negative and HER 2 positive were defined 
as Her 2-enriched type; ER, PR, and HER 2 negative were 
defined as triple negative. The threshold value for ER and 
PR positivity was 1%, for HER 2 positivity was either 
3 positive or 2 positive, and the number of HER 2 gene 
amplifications in chromosome 17 by fluorescence in situ 
hybridization (FISH) was more than 2.2 [6]. According 
to ER, PR, HER2, and ki-67 status the lesions were di-
vided into molecular subtypes (luminal A, luminal B, 
Her 2-enriched, and triple negative). The parameters de-
scribed above were evaluated for each patient.
Statistical analysis
The research data were uploaded to the computer via SPSS 
for Windows 22.0 (SPSS Inc., Chicago, IL) and evaluated. 
Descriptive statistics were presented as mean ± standard 
deviation (minimum-maximum), frequency distribution, 
and percentage. Pearson’s c2 test was used to evaluate cate-
gorical variables. The suitability of the variables to normal 
distribution was examined using visual (histogram and 
probability graphs) and analytical methods (Kolmogorov-
Smirnov/Shapiro-Wilk test). For the variables that were 
not found to fit the normal distribution, the Mann-Whit-
ney U test was used for statistical significance between 
2 independent groups; for 3 and more independent groups 
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Figure 1. A 55-year-old woman with a mass on her left breast. A) Post-contrast with 4-minute delay T1W fat-sat image shows rim-enhancing lesion (white 
arrows). B) Subtraction images. C) DWI. D-E) ADC map (1000 × 10-3 mm2/s) images shows restriction. The pathology result of BI-RADS 5 mass, showing 
type 3 enhancement curve was ER–, PR–, HER2–, invasive ductal carcinoma grade 3, ki67 40%
the Kruskal-Wallis test was used. When a significant dif-
ference was detected between 3 and more independent 
groups, Bonferroni correction was applied in post-hoc 
binary comparisons regarding the source of the difference. 
Statistical significance level was accepted as p < 0.05.
Results
Clinical and histopathological findings
The data of 141 patients were analysed. The mean age was 
51.4 ± 10.1 (min 29; max 75) years. 18.4% (n = 26) of the 
patients were triple negative, 48.9% (n = 69) were luminal B, 
22.7% (n = 32) were luminal A, and 11.3% (n = 16) were 
Her 2-enriched types. 70.9% of the patients were ER+, 
63.1% were PR+, and 68.8% were HER 2–. Lymph node 
involvement was present in 56% of the patients. 
Invasive ductal carcinoma was present in 85.1% of 
the patients, and 88.3% of them had unspecified type of 
invasive ductal carcinoma (IDC NOS). Mixed infiltrative 
type carcinoma was detected in 10% of the patients, 79% 
of which were NOS IDC and lobular carcinoma. Invasive 
lobular carcinoma was observed in 5% of patients. 
MRI features and molecular findings of lesions accord-
ing to histological grades are shown in detail in Table 1. 
Lymph node involvement was higher in patients with 
grade 3 tumours compared to grade 1 and 2. The percent-
age of grade 3 in triple negative tumours was significantly 
higher than grade 1 and 2. ER and PR positivity were 
higher, and HER2 positivity was lower in grade 1 tumours 
compared to grade 2 and 3 (p < 0.05).  
The ratio of grade 1 tumour was higher in luminal A tu-
mours and lower in luminal B tumours (p < 0.05). Axillary 
lymph node involvement was higher in Her 2-enriched tu-
mours compared to other molecular subtypes and lower in 
luminal A tumours (p < 0.001).
Neither molecular subtypes nor tumour grades showed 
any statistically significant difference according to patient’s 
age. 
Magnetic resonance imaging findings
The average size of the lesions was 40.1 × 28.6 mm. 33.3% 
of the lesions were multifocal, 19.1% were multicentric, 
and 1.4% were bilateral. The margin of the lesions was 




Duygu İmre Yetkin, Meltem Gulsun Akpınar, Gamze Durhan et al.  
e272 © Pol J Radiol 2021; 86: e269-e276
in 1.4% of the cases. The shape of the lesions was irregular 
in 89.4%, oval in 8.5%, and round in 2.1% of the cases. Ir-
regular margin was found most frequent in Her 2-enriched 
tumours, spiculated margin was most common in luminal 
B tumours, and circumscribed margin was most common 
in triple negative tumours (p = 0.027). On T2W images, 
44% of the lesions were isointense, 28.3% were hyperin-
tense, and 27.7% were hypointense. The mean ADC value 
was 1.138 × 10-3 mm2/s. 73.8% of the lesions revealed type 3, 
21.2% type 2, and 5% type 1 enhancement patterns. Ac-
cording to the BI-RADS classification, 58.2% of the lesions 
were classified as BI-RADS 5, 34.8% as BI-RADS 6, and 7% 
as BI-RADS 4.
ADC values of lesions according to molecular sub-
types are shown detailed in Table 2. The ADC value of tri-
ple negative tumours was higher compared to luminal A 
and luminal B tumours (p = 0.010 and p = 0.002, respec-
tively).
Rim enhancement was present in 17.7% of patients. It 
was most common in triple negative tumours compared 
to other molecular subtypes (p < 0.01). Type 3 enhance-
ment curve was highest in luminal B tumours, type 2 was 
highest in triple negative tumours, and type 1 was highest 
in luminal A tumours (p = 0.018).
Type 2 and 3 enhancement curves were higher in 
grade 3 tumours, and type 1 enhancement was higher in 
grade 1 tumours (p = 0.029). No statistically significant 
difference was found between ADC values, rim enhance-
ment, multifocality, multicentricity, and tumour grade 
(Table 1).
There was no statistically significant difference found 
between molecular subtypes in terms of T2 intensity, 
shape, BI-RADS category, multifocality, and multicentric-
ity (p > 0.05 for all) (Table 3).
Discussion
The most important findings in this study were higher ra-
tio of ADC values, rim enhancement pattern, type 2 en-
hancement curve, and circumscribed margin features in 
triple negative tumours compared to other molecular sub-
types. On the other hand, T2 intensity, shape, BI-RADS 
category, multifocality, and multicentricity did not show 
any significant difference in triple negative lesions. 
Figure 2. 56-year-old woman with a mass on her left breast. A) Post-contrast with 4-minute delay T1 W fat-sat image shows homogenous enhancing 
lesion (white arrows). B) Subtraction images. C) DWI. D-E) ADC map (824 × 10-3 mm2/s) images shows restriction. The pathology result of BI-RADS 5 mass, 




 Comparison of clinical and magnetic resonance imaging findings of triple-negative breast cancer with non-triple-negative tumours
e273© Pol J Radiol 2021; 86: e269-e276
TNBC constitutes a small portion of all breast cancers, 
approximately 15-20%; however, it is one of the major 
causes of breast cancer-related deaths due to the inability 
to use targeted therapy [12]. Knowing the imaging char-
acteristics of triple negative tumours allows us to predict 
the biological behaviour of the tumour. In patients with 
imaging findings suggest a triple negative tumour and 
in whose pathological report is different from imaging 
findings, MRI features may play an important role in the 
changing treatment plan of the patients by enabling the 
re-evaluation of the pathological specimen.
In our study, the ADC value was higher in triple nega-
tive tumours than in luminal A and luminal B tumours. 
Xie et al. found that the ADC value of triple negative tu-
mours was higher than that of luminal A tumours; how-
ever, no difference was found between luminal B and tri-
Table 1. The distribution of age, lymph node involvement, side of the mass, hormone receptor status, molecular subgroups, and magnetic resonance imaging 
features of lesions according to tumour grade
Parameter Grade I (n = 13) Grade II (n = 60) Grade III (n = 68) pa
Age (year) 50.2 ± 7.3 (42-67) 52.6 ± 10.8 (34-75) 50.5 ± 9.8 (29-70) 0.754
Lymph node involvement, n (%) 4 (30.8) 26 (43.3) 49 (72.1) 0.001
Bilaterality, n (%) 0 2 (3.3) 0 0.531
ER(+), n (%) 13 (100) 51 (85.0) 36 (52.9) < 0.001
PR(+), n (%) 13 (100) 42 (70.0) 34 (50.0) 0.001
Her2Neu(+), n (%) 0 20 (33.3) 24 (35.3) 0.038
Triple negative, n (%) 0 5 (8.3) 19 (27.9) 0.003
Her2 enriched, n (%) 0 4 (6.7) 12 (17.6) 0.059 
Luminal A, n (%) 12 (92.3) 20 (33.3) 0 < 0.001
Luminal B, n (%) 1 (7.7) 31 (51.7) 37 (54.4) 0.007 
Enhancement pattern, n (%)
Type 1 3 (23.1) 3 (5.0) 1 (1.5) 0.029
Type 2 2 (15.4) 13 (21.7) 15 (22.1)
Type 3 8 (61.5) 44 (73.3) 52 (76.4)
Rim enhancement, n (%) 1 (7.7) 10 (16.7) 14 (20.6) 0.515
Multifocality, n (%) 6 (46.2) 20 (33.3) 21 (30.9) 0.564
Multicentricity, n (%) 2 (15.4) 7 (11.7) 18 (26.5) 0.098







MRI – magnetic resonance imaging, ADC – apparent diffusion coefficient. aKruskal-Wallis test 
Table 2. Molecular subtypes and apparent diffusion coefficient (ADC) correlation
Molecular subtype
n/mean ± SD (min-max)
Molecular subtype
n/mean ± SD (min-max)
p-value
Triple (–)e
24/1.287 ± 0.271 (0.878-1.870)
Her-2 enriched
16/1.152 ± 0.216 (0.871-1.624)
0.145
Triple (–)
24/1.287 ± 0.271 (0.878-1.870)
Luminal A
32/1.098 ± 0.189 (0.821-1.793)
0.010
Triple (–)
24/1.287 ± 0.271 (0.878-1.870)
Luminal B
69/1.102 ± 0.270 (0.542-2.391)
0.002
Her-2 enriched
16/1.152 ± 0.216 (0.871-1.624)
Luminal A
32/1.098 ± 0.189 (0.821-1.793)
0.454
Her-2 enriched
16/1.152 ± 0.216 (0.871-1.624)
Luminal B
69/1.102 ± 0.270 (0.542-2.391)
0.345
Luminal A
32/1.098 ± 0.189 (0.821-1.793)
Luminal B
69/1.102 ± 0.270 (0.542-2.391)
0.877
*Mann-Whitney U test. ePost-hoc binary comparisons. ADC – apparent diffusion coefficient
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ple negative tumours [13]. In the study conducted by Youk 
et al., regardless of the PR status, in contrast to our study, 
they found the ADC values of triple negative tumours 
higher than Her 2-enriched tumours [1]. Rapid growth 
and developing intra-tumoural necrosis are responsible 
for higher ADC values [14].
The higher rate of rim enhancement in triple nega-
tive tumours was similar to previous data [1,15]. Overex-
pression of vascular endothelial growth factor and intra- 
tumoral hypoxia are the cause of rim enhancement, which 
is a malignancy indicator [15].
We found a type 2 enhancement curve more frequently 
in the triple negative group. Uematsu et al. found a type 1 
curve to be more frequent in triple negative tumours [14], 
Angelini et al. found no difference in terms of enhance-
ment curves and molecular subtypes [15]. Although the 
type 3 enhancement curve has been defined for malig-
nant lesions, triple negative tumours can show type 1 and 
type 2 enhancement curves and may be confused with 
benign lesions. The contrast enhancement curve alone is 
misleading in distinguishing triple negative tumours from 
benign lesions, and other sequences should be carefully 
evaluated. Circumscribed margin is another misleading 
and confusing MRI feature of triple negative tumours. 
Uematsu et al. found circumscribed margin with MRI 
[14]; Wang et al. found same feature with mammography 
and ultrasound more frequently in TNBC [16].
The grade 3 tumour ratio was higher and the grade 1 
tumour ratio was lower in the triple negative tumours. No 
grade 1 triple negative tumour was detected, as in the study 
by Chas et al. [17]. Type 2 and type 3 enhancement curves 
were more frequently detected in grades 2 and 3 tumours, 
and type 1 enhancement curve was more frequently de-
tected in grade 1 tumours. This was compatible with previ-
ous data [18].
Lymph node involvement was most common in Her 
2-enriched tumours and least common in luminal A tu-
mours. Her 2-enriched tumours progress more aggres-
sively compared to luminal A, and the risk of nodal and 
local recurrence after breast conserving surgery was found 














Enhancement pattern, n (%) 
Type 1 1 (4.2) 0 5 (15.6) 1 (1.4) 0.018
Type 2 7 (29.2) 4 (25.0) 9 (28.1) 10 (14.5)
Type 3 16 (66.7) 12 (75.0) 18 (56.3) 58 (84.1)
Rim enhancement 11 (45.8) 6 (37.5) 2 (6.3) 6 (8.7) < 0.001
Multifocality 10 (41.7) 7 (43.8) 12 (37.5) 18 (26.1) 0.332
Multicentricity 7 (29.2) 5 (31.3) 2 (6.3) 13 (18.8) 0.089
T2 intensity 
Isointense 9 (37.5) 6 (37.5) 19 (59.4) 28 (40.6) 0.159
Hyperintense 11 (45.8) 6 (37.5) 5 (15.6) 18 (26.1)
Hypointense 4 (16.7) 4 (25.0) 8 (25.0) 23 (33.3)
Margin
Non-circumscribed 0.027
 - Spiculated 8 (33.3) 6 (37.5) 17 (53.1) 40 (58.0)
 - Irregular 14 (58.3) 10 (62.5) 15 (46.9) 29 (42.0)
Circumscribed 2 (8.3) 0 0 0
Shape 
Irregular 20 (83.3) 13 (81.3) 31 (96.9) 62 (89.9) 0.453
Oval 3 (12.5) 3 (18.8) 1 (3.1) 5 (7.2)
Round 1 (4.2) 0 0 2 (2.9)
BI-RADS 
IV 1 (4.20) 0 6 (18.8) 3 (4.2)
V 16 (66.7) 9 (56.2) 14 (43.8) 43 (62.3)
VI 7 (29.2) 7 (43.8) 12 (37.5) 23 (33.3)
aKruskal-Wallis test
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to be similar to triple negative tumours [19]. This explains 
the high rate of lymph node involvement in Her 2-enriched 
tumours in our study.
While the majority of malignant breast cancers were 
hypointense on T2W TSE images in the study of Kuhl 
et al., in our patients the tumours were most commonly 
isointense and least commonly hypointense on T2W 
images [20]. T2W hyperintensity is highly suggestive of 
TNBC due to intra-tumoural necrosis, but we found no 
significant difference between T2W intensity and molecu-
lar subtypes. Hasebe et al. suggested that the presence of 
fibrotic foci in necrotic circumscribed tumours may be an 
indicator of repairment, and the outcome may be different 
than without fibrotic foci [21]. In our study, the lack of 
difference between the groups in T2W images may be due 
to the presence of more fibrotic foci in TNBC tumours. 
This may indicate that there are different subtypes of triple 
negative tumours. Since there was no follow-up of the pa-
tients in our study, we cannot comment about the patient 
outcome and survey.
Multifocal lesions were observed in 33.3% and mul-
ticentric lesions in 19.1% of the patients. In the study of 
Neri et al., the rate of multifocality was 11.3% and the 
rate of multicentricity was 5.2%; these rates were very low 
compared to our study [22]. The reason for this discrep-
ancy is that in the vast majority of patients with existing 
MRI, the indication for breast MRI is local advanced stage 
breast cancer, and the evaluation of the response of the 
tumour to the treatment before and after neoadjuvant 
chemotherapy.
As stated in the study of Choi et al., no relationship 
was found between tumour grade and ADC value in our 
study [23]. This may be due to TNBCs in the grade 3 
group despite higher ADC values.
The retrospective nature of our study and the relatively 
low number of patients with triple negative tumours com-
pared to luminal A and B, the lower number of invasive 
lobular and mixed infiltrative cancer compared to invasive 
ductal cancer, and no follow-up of patients were the limi-
tations of our study. Another limitation of our study was 
the exclusion of the non-mass-forming lesions. Because 
these lesions grow with a remaining normal parenchyma 
and this normal parenchyma may lead to erroneous re-
sults in ADC measurements, we decided to exclude these 
cases. MRI finding of a significant part of patients with 
lobular cancer is non mass enhancement. Thus, this may 
lead to a lower number of patients with lobular cancer in 
our study and inclusion of the patients with lobular cancer 
into the BI-RADS 4 category.
Conclusions
Higher ADC values, rim enhancement, and circum-
scribed margin are the distinctive features of TNBC tu-
mours. The distinctive MRI features of TNBC should be 
well known. While the typical features of the TNBC tu-
mour on MRI are present, if the pathology report is com-
patible with a different subtype, the pathologist should be 
informed of the situation, and the pathological specimen 
should be re-evaluated. This is very important to plan the 
patient’s treatment and may prevent unnecessary targeted 
therapies.
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